In the Oct. 12 issue of BioWorld Today, an article on acollaboration between Gensia Inc., of San Diego, and BoehringerMannheim Pharmaceuticals Corp., of Gaithersburg, Md., shouldhave said the companies expect to file an abbreviated new drugapplication (ANDA) with the FDA in the first half of 1995 for acardiovascular treatment based on Geomatrix controlled drugdelivery technology and nifedipine.In addition, two of three milestone payments from Boehringer toGensia are based on submitting the ANDA and gaining FDAapproval of the application.

(c) 1997 American Health Consultants. All rights reserved.